Taconic Biosciences' Dr. Azusa Tanaka and Dr. Michael Seiler penned this Drug Discovery World article regarding NK (natural killer) cell therapy and how this will transform immunotherapy:
"Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours - a major shift in oncology treatment.
Yet even this groundbreaking therapy has limitations, such as when patients already immuno-depressed from a first-line treatment do not have sufficient T-cells to modify or stimulate. For this reason, investigators are looking to NK (natural killer) cell therapy as the next frontier of immunotherapy." Read* the complete article at: DDW-Online.com
"Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours - a major shift in oncology treatment.Yet even this groundbreaking therapy has limitations, such as when patients already immuno-depressed from a first-line treatment do not have sufficient T-cells to modify or stimulate. For this reason, investigators are looking to NK (natural killer) cell therapy as the next frontier of immunotherapy."